- Home
- MYFW vs IPHA Comparison
MYFW vs IPHA Comparison
Compare MYFW & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MYFW | IPHA |
|---|---|---|
| Founded | 2002 | 1999 |
| Country | United States | France |
| Employees | N/A | 174 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.6M | 119.1M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | MYFW | IPHA |
|---|---|---|
| Price | $24.52 | $1.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $24.25 | $5.75 |
| AVG Volume (30 Days) | ★ 19.7K | 11.9K |
| Earning Date | 04-23-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.02 | N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $96,914,000.00 | N/A |
| Revenue This Year | $20.48 | $28.31 |
| Revenue Next Year | $9.70 | N/A |
| P/E Ratio | $18.21 | ★ N/A |
| Revenue Growth | ★ 7.60 | N/A |
| 52 Week Low | $17.55 | $1.31 |
| 52 Week High | $28.00 | $2.63 |
Technical Indicators
Market Signals| Indicator | MYFW | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 21.88 |
| Support Level | $22.09 | N/A |
| Resistance Level | $26.27 | $1.88 |
| Average True Range (ATR) | 0.75 | 0.08 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 64.37 | 2.79 |
Price Performance
Historical ComparisonAbout MYFW First Western Financial Inc.
First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.